Your session is about to expire
← Back to Search
Beta Blocker
Timolol Ophthalmic Suspension 0.5 Percent for Ocular Hypertension
Phase 2
Waitlist Available
Research Sponsored by Betaliq, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Willing and able to understand and sign an informed consent form prior to any study related procedures.
Able to administer or have a caregiver accurately administer an eye drop.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 15: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 42: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 84: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes
Awards & highlights
Study Summary
This study is evaluating whether a drug that lowers blood pressure can be used to treat glaucoma.
Eligible Conditions
- Ocular Hypertension
- Open-Angle Glaucoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 15: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 42: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 84: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 15: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 42: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 84: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Intraocular Pressure Over 84 Days
Secondary outcome measures
Intraocular Pressure: Change from Baseline at All Time Points at Each Visit
Intraocular Pressure: Change from Baseline in Diurnal IOP at Each Visit
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Timolol Ophthalmic Suspension 0.5 PercentExperimental Treatment1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Group II: Nebivolol Ophthalmic Suspension 1 PercentExperimental Treatment1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Group III: Nebivolol Ophthalmic Suspension 0.5 PercentExperimental Treatment1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Group IV: Timolol Ophthalmic Solution 0.5 PercentActive Control1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nebivolol Ophthalmic Suspension 1 Percent
2021
Completed Phase 2
~230
Nebivolol Ophthalmic Suspension 0.5 Percent
2021
Completed Phase 2
~230
Timolol Ophthalmic Suspension 0.5 Percent
2021
Completed Phase 2
~230
Find a Location
Who is running the clinical trial?
Betaliq, Inc.Lead Sponsor
Trial Runners, LLCOTHER
3 Previous Clinical Trials
365 Total Patients Enrolled
Summit Analytical, LLCUNKNOWN
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger